|Videos|December 25, 2019
HER2+ mBC: DESTINY-Breast04 Trial
Author(s)Sponsored Content
The comparison of trastuzumab deruxtecan (DS-8201a) with standard chemotherapy is examined for patients with low levels of HER2 metastatic breast cancer and final thoughts on the future treatment landscape of HER2+ breast cancer.
Advertisement
The comparison of trastuzumab deruxtecan (DS-8201a) with standard chemotherapy is examined for patients with low levels of HER2 metastatic breast cancer and final thoughts on the future treatment landscape of HER2+ breast cancer.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Darzalex Faspro in High-Risk Smoldering Multiple Myeloma
2
Top Lung Cancer Stories from October: Insights, and Patient Journeys
3
Myeloma Advocate Stresses Support for Caregivers in Black Community
4
October Treatment Advances and Survivorship Perspectives in GU Cancers
5
